Physician profile
Arnab Ray
NPI 1922155720
$26,158.66
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2021: $192 · 2022: $6,549 · 2023: $19K · 2024: $82.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,370 · Consulting Fee: $7,905 · Education: $1,160 · Travel and Lodging: $1,058 · Food and Beverage: $639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,370.00 |
| Consulting Fee | $7,905.00 |
| Education | $1,160.00 |
| Travel and Lodging | $1,058.17 |
| Food and Beverage | $639.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $25,217.83 | 2019-2023 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $150.00 | 2022 | |
| Gilead Sciences, INC. | $142.34 | 2022-2024 | Epclusa |
| Allergan, INC. | $127.88 | 2019 | |
| Erbe USA INC | $120.00 | 2021 | |
| Abbvie INC. | $119.99 | 2019 | |
| Pentax of America, INC. | $110.93 | 2022 | |
| Boston Scientific Corporation | $86.92 | 2021-2023 | Spyglass |
| Enterra Medical, INC. | $60.46 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $22.31 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnab Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.